ABSTRACT
The major commercial immune globulin is γ-globulin, better known as immunoglobulin G (IgG), which is available as an intramuscular immune globulin (IMG), as an IVIG, and, more recently, as a subcutaneous product (SCIG). Only small amounts of that product may be given by intramuscular injection, and this technique is limited to high-titer immune globulins.7,8 There has been only limited development of the members of immunoglobulin classes, other than IgG, as therapeutic products. There has been some interest in a therapeutic concentrate of immunoglobulin M (IgM).9,10 A humanized monoclonal IgM, panobacumab, has been evaluated for pharmacokinetics and safety in patients with Pseudomonas aeruginosa pneumonia.11
